Traynor Capital Management Inc. bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,730 shares of the medical research company’s stock, valued at approximately $201,000.

Other institutional investors have also made changes to their positions in the company. First Mercantile Trust Co. acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $723,000. DekaBank Deutsche Girozentrale raised its position in shares of Edwards Lifesciences Corporation by 3.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 188,912 shares of the medical research company’s stock worth $22,251,000 after buying an additional 5,437 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Edwards Lifesciences Corporation by 3.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 658,588 shares of the medical research company’s stock worth $77,872,000 after buying an additional 19,490 shares during the last quarter. Wetherby Asset Management Inc. acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $206,000. Finally, Cigna Investments Inc. New acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $971,000. 84.15% of the stock is currently owned by institutional investors.

Edwards Lifesciences Corporation (NYSE EW) opened at 114.50 on Friday. The company has a market capitalization of $24.18 billion, a P/E ratio of 34.73 and a beta of 0.63. The company’s 50-day moving average price is $116.95 and its 200-day moving average price is $105.35. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. During the same period in the previous year, the firm earned $0.76 earnings per share. The company’s revenue was up 10.9% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/1730-shares-in-edwards-lifesciences-corporation-nyseew-acquired-by-traynor-capital-management-inc/1477686.html.

A number of brokerages have issued reports on EW. Canaccord Genuity reaffirmed a “buy” rating and issued a $155.00 target price (up from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Cowen and Company reaffirmed an “outperform” rating and issued a $135.00 target price (up from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Barclays PLC upped their target price on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, July 27th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $130.00 target price (up from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $121.13.

In other news, VP Donald E. Bobo, Jr. sold 25,000 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total value of $3,883,845.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,412 shares of company stock valued at $21,176,230. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.